Merck shareholders bless deal for Schering

It's official: Merck got shareholder approval for its $41 billion merger with Schering-Plough, with preliminary vote results showing that more than 99 percent of the stockholders gave a thumbs-up to the deal. Release

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.